Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals shares rise with tech‑biotech rally, but gains driven by market momentum; analysts keep “Buy” ratings and target $425‑$510 per share.

Alnylam partners with Tenaya Biosciences to accelerate RNAi therapies for cardiovascular disease, targeting PCSK9 and other genes to lower LDL‑C and reduce atherosclerosis risk.

Alnylam’s new partnerships with Tenaya Therapeutics and Helix boost its RNAi portfolio, driving precision cardiology and data‑powered target discovery for future growth.

Alnylam’s Q4 2025 earnings beat forecasts, driven by Onpattro sales, a solid pipeline, and value‑based pricing—yet patent cliffs and rising competition pose risks to future growth.

Alnylam’s Q4 2025 results turn a loss into a $45 M profit, fueled by $1.78 B in product revenue from its first‑in‑class ASO and siRNA therapies, and a 2026 outlook of $3.4‑$3.8 B in growth.

Alnylam’s Amvuttra sales slowdown prompts Bernstein to cut its price target, but the company’s RNAi pipeline and upcoming J.P. Morgan conference may boost investor confidence.

Alnylam hires Vertex veteran Stuart Arbuckle to sharpen regulatory strategy and fast‑track its RNA‑silencing pipeline, boosting market‑launch prospects.

Alnylam boosts siRNA capacity with a $250 M expansion in Massachusetts and gains a new Canadian indication for AMVUTTRA®, poised to cut costs, lift margins, and broaden its therapeutic reach.

Alnylam’s Health Canada approval for AMVUTTRA and Nasdaq‑100 inclusion boost its RNA‑i pipeline and market reach, promising revenue gains amid manufacturing and reimbursement challenges.

Alnylam’s Nasdaq‑100 debut boosts its RNAi drug pipeline and investor visibility, highlighting breakthroughs in liver, eye, and CNS gene‑silencing therapies.